This article analyzes pharmaceutical IP challenges like high drug prices and data exclusivity. It proposes solutions for healthcare executives and policymakers, focusing on improving drug access, refocusing R&D incentives, and promoting knowledge sharing to balance innovation with public health needs.
Medicaid fraud significantly impacts healthcare costs and access for millions. We examine data analytics and compliance strategies to combat systemic waste and protect program integrity.
